Investors & Media
We are a clinical stage chemoprotection oncology company focused on developing medicines to make chemotherapy safer and thereby more effective to save more patients’ lives.
ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, focusing exclusively on treating patients with p53-mutated cancers.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
August 15, 2022Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 1, 2022Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer
July 8, 2022Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022
To develop a targeted drug that prevents chemotherapy-induced side effects to help patients fight cancer more effectively with a better quality of lifeOUR VISION:
To bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy